India Pharma Outlook Team | Thursday, 20 November 2025
HRV Pharma has announced a significant CDMO partnership with MetroChem API, marking one of India’s standout moves in advanced API development.
Revealed today, the multi-year agreement positions HRV Pharma’s Virtual API platform alongside MetroChem’s deep chemistry and manufacturing strength to accelerate high-value NCE-1 and late-stage complex APIs for regulated and semi-regulated markets.
The collaboration blends HRV’s global reach across more than 50 countries with MetroChem’s proven scale-up expertise and strong GMP infrastructure.
Together, the companies will drive exclusive and semi-exclusive development, scale-up and end-to-end GMP manufacturing for multiple strategic molecules. The scope includes validation, global supply, and a unified approach to regulatory filings covering the US, EU, LATAM, MENA and APAC.
Also Read: Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings
“Speaking on this unique partnership, Hari Kiran Chereddi, CEO of HRV Pharma, said, “This collaboration is a natural extension of HRV’s strategy to build a next-generation, Virtual API ecosystem that scales Indian innovation to global markets. MetroChem’s chemistry depth, combined with our global regulatory and market expansion engine, creates a powerful platform for developing and commercializing high-value APIs with speed, quality and predictability.”
Harsha Nandepu, COO of MetroChem added, “Partnering with HRV aligns with MetroChem’s vision of moving deeper into complex NCE-1 and advanced API development. Together, we bring complementary strengths strong process chemistry, robust GMP operations, and HRV’s regulatory and global commercial reach. This partnership allows us to meaningfully expand our innovation footprint, monetize our R&D and deliver world-class solutions to global pharma.”
The agreement launches with five priority programs and room for an expanded pipeline. Both teams will jointly manage CMC documentation, stability studies, validation and global regulatory engagement—strengthening India’s position as a rising force in specialty and complex API development.
